Detalhe da pesquisa
1.
Developing a dashboard for benchmarking the productivity of a medication therapy management program.
J Am Pharm Assoc (2003)
; 57(1): 95-101.e1, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-27964887
2.
Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019.
Mayo Clin Proc
; 97(5): 943-950, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35512884
3.
Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
Mayo Clin Proc
; 97(9): 1641-1648, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36058578